Calcium-dependent Interaction of S100B with the
C-terminal Domain of the Tumor Suppressor p53*
Christian
Delphin
,
Michel
Ronjat§,
Jean Christophe
Deloulme
,
Gérome
Garin¶,
Laurent
Debussche
,
Yuichiro
Higashimoto**,
Kazuyasu
Sakaguchi**, and
Jacques
Baudier

From the
Département de Biologie
Moléculaire et Structurale du Commissariat à Energie
Atomique, INSERM Unité 244, the ¶ Laboratoire de Chimie des
Protéines, and the § Laboratoire Canaux Ioniques et
Signalization, Centre d' Etudes Nucléaire-Grenoble, 38054 Grenoble, France, the
Rhône-Poulenc Rorer, Centre de
Recherche de Vitry-Alfortville, 13 quai Jules Guesde, 94403 Vitry sur
Seine Cedex, France, and the ** Laboratory of Cell Biology, National
Institutes of Health, Bethesda, Maryland 20892
 |
ABSTRACT |
In vitro, the S100B protein interacts
with baculovirus recombinant p53 protein and protects p53 from thermal
denaturation. This effect is isoform-specific and is not observed with
S100A1, S100A6, or calmodulin. Using truncated p53 proteins in the
N-terminal (p531-320) and C-terminal
(p5373-393) domains, we localized the S100B-binding region
to the C-terminal region of p53. We have confirmed a
calcium-dependent interaction of the S100B with a synthetic
peptide corresponding to the C-terminal region of p53 (residues
319-393 in human p53) using plasmon resonance experiments on a BIAcore
system. In the presence of calcium, the equilibrium affinity of the
S100B for the C-terminal region of p53 immobilized on the sensor chip
was 24 ± 10 nM. To narrow down the region within p53
involved in S100B binding, two synthetic peptides,
O1357-381 (residues 357-381 in mouse p53) and
YF-O2320-346 (residues 320-346 in mouse p53), covering
the C-terminal region of p53 were compared for their interaction with
purified S100B. Only YF-O2 peptide interacts with S100B with high
affinity. The YF-O2 motif is a critical determinant for the
thermostability of p53 and also corresponds to a domain responsible for
cytoplasmic sequestration of p53. Our results may explain the rescue of
nuclear wild type p53 activities by S100B in fibroblast cell lines
expressing the temperature-sensitive p53val135 mutant at the
nonpermissive temperature.
 |
INTRODUCTION |
The S100 family is one of the largest subfamily of calcium-binding
proteins that are thought to play roles in mediating calcium signals
during cell growth, differentiation, and motility (reviewed in Ref. 1).
These proteins are characterized by highly conserved helix-loop-helix
calcium-binding domains, known as EF-hand motifs. The S100B is found in
astroglial cells in the central nervous system but also in a number of
tissues outside the nervous system, including adipose tissue, testis,
skin, and lymphocytes (2). In cultured cells, synthesis of S100B is
tightly regulated and is maximum in the G1 phase of the
cell cycle (3-5). The S100B protein is a noncovalent homodimer formed
by the association of two S100-
subunits (6, 7). Calcium binding
induces conformational changes in the protein structure (8-10),
destabilizing the S100B quaternary structure and allowing interaction
with target proteins (7-12). For example, the
Ca2+-dependent binding of S100B to microtubules
(13), GFAP (14), Ndr protein kinase (15), and p53 (16) has been
demonstrated. The identification of S100B target proteins is essential
to better understand the mechanisms underlying S100B functions. Like
calmodulin, S100B is likely to regulate multiple target proteins.
The tumor suppressor p53 protein (17) is a putative intracellular
target for the S100B protein. In vitro, S100B binds to p53
and inhibits p53 aggregation and phosphorylation by PKC
(16).1 S100B also binds to a
peptide derived from the extreme C-terminal end of p53 (12, 18). A
functional interaction between S100B and p53 was recently
demonstrated in p53-negative mouse embryo fibroblasts by sequential
transfection with the S100B and temperature-sensitive p53val135 genes
(5). In mouse embryo fibroblast cells expressing a low level of
p53val135, S100B cooperates with calcium in triggering p53val135-dependent cell growth arrest and death at the
nonpermissive temperature (37.5 °C). Activation of wild type p53
functions by S100B correlated with nuclear accumulation of p53val135
under a wild type conformation. S100B modulation of p53val135 functions was confirmed in the rat embryo fibroblast (REF) cell line clone 6, which is transformed by oncogenic Ha-ras and overexpression of p53val135 (19). Ectopic expression of S100B in clone 6 cells reverts
transformed phenotypes and restores wild type p53 activities at
37.5 °C (5). We have hypothesized that S100B could either inactivate
the mutant p53val135 species and/or favor folding of the p53val135
under a wild type conformation (5).
The functional activity of the p53val135 mutant is associated with its
conformational flexibility (20). At the nonpermissive temperature
(37.5 °C), the temperature-sensitive p53val135 mutant folds into an
inactive mutant conformational form, detectable by the monoclonal
antibody PAb240. At the permissive temperature, the p53val135 protein
adopts a wild type conformation detectable by the monoclonal antibody
PAb246 and is functionally active (i.e. able to specifically
bind DNA and to activate transcription). The conformational flexibility
that characterizes the temperature-sensitive p53val135 mutant is not
unique to this mutation and could be representative of the
conformational flexibility that also characterizes wild type p53 (20,
21). In vivo, conformational shift between the wild type and
mutant conformations (recognized by the monoclonal antibodies PAb246
and PAb240, respectively) has been observed during embryonic
differentiation of embryonic stem cells (22). In vitro, wild
type conformation of Escherichia coli expressed recombinant
p53 can be allosterically regulated for stabilization by two regulatory
sites found within the N and C termini of the molecule to which ligands
may bind (23). A major challenge now is to characterize the
domain on p53 associated with conformational shift and to identify the
cellular co-factors that may govern the conformational switch
controlling p53 activity (20).
In this report, we show that the S100B protein interacts with
baculovirus recombinant p53 and protects p53 from thermal denaturation. We also identify a high affinity S100B-binding domain within p53 called
YF-O2 (residues 320-346 in mouse p53). This domain constitutes a
critical determinant for the stability and oligomerization status of
p53 (24-26). It corresponds to the minimal region of the C terminus that confers thermal instability to p53 (25) and also corresponds to a
domain responsible for cytoplasmic sequestration of p53 (27).
 |
MATERIALS AND METHODS |
Peptides--
The p53319-393 peptide was
synthesized as described previously (28). The peptide was dissolved in
20 mM HEPES-NaOH, pH 7.5, at the concentration of 98 µM. Other peptides were synthesized by the solid phase
method, using Fmoc (fluoren-9-ylmethoxycarbonyl) chemistry on an
Applied Biosystems 430A peptide synthesizer. The O1 peptide, which
encompasses the PKC phosphorylation site domain, corresponds to
residues 357-381 within mouse p53: RAHSSYLKTKKGQSTSRHKKTMVKK. The
peptide was dissolved in 20 mM Tris-HCl, pH 7.5, at the
concentration of 100-200 µM. YF-O2 peptide has the
following sequence: YFTLKIRGRKRFEMFRELNEALELKD and corresponds to
residues 321-346 within mouse p53. W-O2 peptide is a mutated version
of YF-O2, and Tyr321 and Phe322 were both
substituted with Trp residues. YF-O2 and W-O2 peptides were dissolved
in 10 mM HEPES-HCl, pH 2.5, at the concentration of
200-400 µM. Peptide stock solutions were stored at
20 °C.
Proteins--
S100B, S100A1, and calmodulin were purified from
bovine brain (10). Recombinant Human p53 was expressed in SF9 cells and purified to homogeneity by S100B affinity chromatography as described previously (16). To express truncated human p53, corresponding cDNA
fragments were generated from full-length human p53 by polymerase chain
reaction (oligonucleotide sequences available upon request). After
verification of DNA sequences, c-DNA fragments were inserted into
pBlueBac III vector (Invitrogen). Expression in insect cells and
interaction with S100B-Sepharose column were as described (16).
Electrophoretic Mobility Shift Assays--
The method used was
identical to that previously published (29). To study the effect of
S100B and other related calcium-binding proteins on p53 DNA binding
activity, purified p53 was first incubated in the presence or in the
absence of calcium-binding proteins for 15 min at 30 °C in 20 mM Tris-HCl buffer, pH 7.5, 110 mM KCl, 5 mM dithiothreitol, and 1 mM CaCl2.
The proteins were then mixed with 1 ng of labeled DNA, further
incubated at 4 °C for 10 min prior to electrophoresis onto a 5%
nondenaturing polyacrylamide gel, and run in buffer containing 10 mM Hepes, 10 mM Tris, pH 8.0, and 0.5 mM CaCl2.
Real Time Surface Plasmon Resonance Recording--
Real time
binding experiments were performed on a BIAcore biosensor system
(Pharmacia Biosensor AB, Uppsala, Sweden). All experiments were
performed at 25 °C. p53319-393 peptide (35 µl of 1 µM peptide in 10 mM sodium acetate, pH 3.5) was directly coupled through its amino groups to the sensor surface activated by N-hydroxy-succinimide and
N-ethyl-N'-(dimethylaminopropyl)carbodiimide according to the manufacturer's instructions. The remaining reactive groups were then inactivated with 1 mM ethanolamine. For
control experiments, sensor surface was treated as above in the absence of peptide. All interaction experiments were done using a running buffer containing 20 mM Tris-HCl, pH 7.5, 120 mM NaCl, 1 mM CaCl2. Between
injections, the sensor chip was washed with a buffer containing 20 mM Tris-HCl, pH 7.5, 120 mM NaCl, 2 mM EDTA. Sensorgrams were analyzed using BIAevaluation 3.0 program (Pharmacia Biosensor AB) and kinetic constants were obtained by
fittings curves to a single-site binding model (A + B = AB).
Protein Kinase C Activity Assay and PKC Inhibitor Assay--
The
PKC assays were performed as described previously (30). To analyze the
effect of S100B and other calcium-binding proteins on the inhibitor
capacity of YF-O2 or W-O2 peptides, the following procedure was used.
10 µl of diluted inhibitor peptides in H2O (1:4000-1:50
dilution of stock solution) were mixed in Eppendorf tubes with
increasing concentration of calcium-binding proteins in 30 µl of 50 mM Tris-HCl buffer, pH 8.0, 0.5 mM
CaCl2. 10 µl of PKC was subsequently added to each tube
to reach a final concentration of 3 nM, and the protein
mixture was vortex-mixed. The phosphorylation reaction was immediately
initiated by the addition of 20 µl of a mixture containing O1 peptide
used as substrate at 8 µM final concentration plus
MgCl2, phosphatidylserine, dioleoylglycerol, and
[
-32P]ATP at final concentrations used in standard PKC
assay (30).
Native Gel Electrophoresis--
Gels containing 13% acrylamide,
0.375 M Tris-HCl, pH 8.3, and 0.5 mM
CaCl2 or 1 mM EGTA were prepared without
stacking gel. W-O2 peptide and S100B were incubated in 40 mM Tris-HCl, pH 8.0, 0.2 M NaCl, 5 mM dithiothreitol, 15% glycerol, and 0.5 mM
CaCl2 or 1 mM EGTA for 5 min on ice prior to
electrophoresis. The gels were run at 20 mA. The electrode buffer
consisted of 25 mM Tris, 192 mM glycine, and
0.5 mM CaCl2 or 1 mM EGTA. The gels
were stained with Coomassie Blue.
Fluorescence Measurements--
The fluorescence measurements
were performed with a Perkin-Elmer spectrofluorometer in 25 mM Tris-HCl, pH 7.5, 0.12 M NaCl containing
either 0.1 mM CaCl2 or 2 mM EGTA.
For titration experiments, excitation was at 280 nm, and emission was
monitored at 340 nm.
 |
RESULTS |
S100B Protects p53 from Thermal Denaturation--
Heating
baculovirus recombinant p53 at 30 °C for 15 min leads to
self-aggregation (16) and permanent loss of DNA binding activity (Fig.
1A; see also Ref. 23). S100B
protein, which prevents p53 from temperature-dependent
aggregation (16), counteracts the temperature-dependent
inhibition of p53 DNA binding activity (Fig. 1B, lanes
1 and 2). The S100B effect is specific because calmodulin, S100A1 and S100A6 have no effect (Fig. 1B,
lanes 3-5). The dose response experiment shown in Fig.
1C reveals that the S100B concentrations required to protect
the DNA binding activity of p53 from thermal inhibition are similar to
those required to protect p53 from temperature-dependent
aggregation (16). S100B was only able to activate p53 for DNA binding
if preincubated with p53 at 30 °C. S100B was not able to activate
p53 for DNA binding when incubated at 4 °C, and it did not
reactivate DNA binding activity of denatured p53 (data not shown). Thus
the effect of S100B is limited to protection of p53 from thermal
denaturation. In that respect, S100B behaves differently from PAb421.
PAb421 binds to the extreme C terminus of p53 to activate p53 DNA
binding but does not protect p53 from thermal denaturation (23).

View larger version (58K):
[in this window]
[in a new window]
|
Fig. 1.
The effect of S100B on thermal denaturation
of p53. A, effect of temperature on DNA binding
activity of p53. Increasing amounts of murine p53 as indicated were
incubated for 15 min at 30 °C (lanes 1-4) or at 4 °C
(lanes 5-8). The proteins were then mixed with 1 ng of
labeled DNA and further incubated at 4 °C for 10 min prior to
electrophoresis. B, S100B counteracts the
temperature-dependent inhibition of p53-DNA binding. p53
(0.1 µg) was incubated for 15 min at 30 °C in the absence
(lane 1) or in the presence of 1 µM of S100B
(lane 2), calmodulin (lane 3), S100A1 (lane
4), or S100A6 (lane 5). The proteins were then mixed
with 1 ng of labeled DNA and further incubated at 4 °C for 10 min
prior to electrophoresis. C, S100B titration of maximal
stabilization of the DNA binding activity of p53 at 30 °C. 1 µM p53 was first incubated for 15 min at 30 °C in the
absence (lane 1) or in the presence of increasing amount of
S100B (lanes 2-6) as indicated. The proteins were mixed
with 1 ng of labeled DNA and 20 ng of unlabeled DNA.
|
|
Mapping of the Minimal S100B-binding Domain on
p53--
Recombinant human p53 (p531-393) expressed in
SF9 cells accumulates in the cytoplasm and in the nuclei of infected
cells. Both cytoplasmic and nuclear recombinant human p53 bind to
S100B-Sepharose column in the presence of calcium and are eluted with
buffer containing EGTA (Fig.
2A). We next compared the
binding to S100B-Sepharose of human p53 fragments that lacks the
C-terminal (p531-320) (Fig. 2B) or N-terminal
(p5373-393) domain (Fig. 2C).
p531-320 that lacks nuclear localization signals (31)
accumulates within the cytoplasm of infected cells, whereas
p5373-393 is predominantly present within the cell nuclei.
Cell extracts enriched with each of these p53 fragments were loaded
onto a S100B-Sepharose column, and the calcium-dependent
binding of the p53 fragments to the column was analyzed by
SDS-polyacrylamide gel electrophoresis, followed by Western blot
analysis using monoclonal antibodies directed against N-terminal or
C-terminal epitopes (Fig. 2, B and C).
p531-320 that lacks the C-terminal domain does not bind to
S100B and was recovered in the flow-through fractions (Fig.
2B). Only p5373-393 efficiently binds to the
S100B column in the presence of calcium and is eluted with buffer
containing EGTA (Fig. 2C). Hence, the S100B-binding region
is localized to the C-terminal region of the p53 protein (residues
320-393) (Fig. 3).

View larger version (41K):
[in this window]
[in a new window]
|
Fig. 2.
The interaction of p53 with
S100B-Sepharose. Insect cells were infected with different
recombinant baculoviruses expressing full-length human p53 (1-393)
(A) or truncated p53, p53 (1-320) (B), or p53
(73-393) (C). Cell extracts were loaded onto
S100B-Sepharose columns (1 × 0.5 cm). Columns were washed with 10 column volumes of buffer containing 0.5 mM
CaCl2, and bound proteins were eluted with buffer
containing 4 mM EGTA. Proteins in the loading samples
(lanes 1), in column flow-through fractions (lanes
2), and in fractions eluted with EGTA (lanes 3)
were subjected to 11% SDS-polyacrylamide gel electrophoresis. Gels
were either Coomassie Blue-stained (Stain.) or transferred
to nitrocellulose membranes, and the proteins were revealed by Western
blot (W.B.) using monoclonal antibodies DO1 (B)
or PAb421 (C).
|
|

View larger version (7K):
[in this window]
[in a new window]
|
Fig. 3.
The C-terminal region of p53. Amino acid
sequence of the C-terminal region of human p53 involved in binding to
S100B protein. This region is sufficient to transform primary
fibroblasts in cooperation with ras. The minimal domain
required for cell transformation is in bold (44). The oligomerization
(28) and cytoplasmic sequestration domain is boxed (27). The
putative PKC phosphorylation sites and PAb421 epitope are indicated
(30). The mouse YF-O2 and O1 peptide sequences used in this study are
also presented.
|
|
The molecular interaction between S100B and the C-terminal region of
p53 was then analyzed using surface plasmon resonance detection (Fig.
4). A synthetic peptide corresponding to
human p53319-393 was coupled to the biosensor chip through
amino functions. Fig. 4A shows a typical sensorgram
representing the real time interaction between purified
Ca2+-bound S100B and the p53319-393 peptide.
The S100B-p53319-393 interaction is strictly dependent on
the presence of Ca2+ and completely reversed by
addition of EDTA (Fig. 4A). We controlled that there is
absolutely no interaction of S100B with a biosensor ship with no
peptide immobilized and neutralized with ethanolamine (Fig.
4A). The reversibility of the
S100B-p53319-393 interaction allows recycling the
biosensor chip with EDTA containing buffer and to perform a
dose-dependent titration of the interaction utilizing the
same biosensor chip (Fig. 4B). At low S100B concentrations (10-100 nM) the kinetics of interactions could be fitted
with a single interaction site model and an apparent equilibrium
affinity of S100B for p53319-393 of 25 ± 10 nM. At higher S100B concentrations (100-900
nM), kinetics of interaction could barely be fitted with a
single site model may be due to titration of lower affinity sites (see
"Discussion"). The specificity of the high affinity
Ca2+-dependent interaction between
p53319-393 and S100B was confirmed by comparison with two
other related EF-hand calcium-binding proteins, S100A1 and calmodulin
(Fig. 4C, inset). Neither S100A1 nor calmodulin
was able to interact with the p53319-393-coated sensorship
(Fig. 4C).

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 4.
Characterization of the interaction of
purified S100B with p53319-393 using surface plasmon
resonance detection. p53319-393 peptide was
covalently immobilized on the sensor surface as described under
"Materials and Methods." Running buffer contains 20 mM
Tris-HCl, pH 7.5, 120 mM NaCl, 1 mM
CaCl2. The different sensorgrams shown here have been
obtained on the same sensor surface except for the control. Three
different sensor surfaces coated with p53319-393 peptide
gave similar results with respect to their interaction with the
different proteins. A, S100B (90 nM in running
buffer) was injected. At the end of injection, the sensor surface was
washed with running buffer and then with a buffer containing 2 mM EDTA. Because of the high resonance signal induced by
EDTA, the dissociation of S100B is only visible after the end of the
injection of the EDTA buffer. S100B (90 nM in running
buffer) was preincubated with WF-02 peptide (1 µM) prior
to injection (S100B-W-O2). Control corresponds to the injection of
S100B on a sensor surface treated in the absence of
p53319-393 peptide. B, concentration dependence
interaction of S100B with p53319-393. Increasing
concentration of S100B was injected in running buffer on the sensor
surface coated with 11.25 nM (a), 30 nM (b), 45 nM (c), 60 nM (d), or 90 nM (e) of
p53319-393 peptide. Control is as in A.
C, the interaction of S100B (90 nM) with
p53319-393 immobilized on the sensor chip surface is
compared with S100A1 (90 nM) and calmodulin (90 nM). Insert shows SDS-polyacrylamide gel electrophoresis
and Coomassie Blue staining of the purified bovine brain S100A1
(lane 1), S100B (lane 2), and calmodulin
(lane 3) used in that study. The asterisks
indicate position of covalent S100A1 and S100B dimers.
|
|
Molecular Mapping of the High Affinity S100B-binding Site on
p53--
To define in further detail the high affinity S100B-binding
region within p53319-393, two synthetic peptides
corresponding to putative S100B-binding sites within the C-terminal
domain of p53 were synthesized and assessed for their capacity to
interact with purified S100B (Fig. 3).
The first peptide called O1357-381 (residues 357-381 in
mouse p53) shows similarities with the S100B and calmodulin-binding
domain of the MARCKS protein (16). Like its cognate peptide on MARCKS, O1 peptide is phosphorylated by PKC in vitro on multiple
sites (30). Because binding of S100B to p53 inhibits p53
phosphorylation by PKC (16), we analyzed the effect of S100B on
PKC-mediated phosphorylation of O1. As shown in Fig.
5, addition of S100B
(O1357-381:S100B molar ratio 0.5) had no effect on the
phosphorylation of O1357-381 by PKC. On the
contrary, monoclonal antibody PAb421 that binds to
O1357-381 inhibited phosphorylation by PKC. PAb242, which
does not bind to O1357-381, had no effect on its
phosphorylation. These results suggest that the high affinity
S100-binding domain within p53 is distinct from O1357-381.
In further support of that conclusion, O1 peptide at the concentration of 1 µM did not antagonize S100B binding to the
p53319-393-coated sensorship (not shown).

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 5.
PAb421 but not S100B inhibits O1
phosphorylation by PKC. O1 (2 µM) phosphorylation by
PKC was studied in the presence of increasing amounts of monoclonal
antibodies PAb421 (molar ratio as indicated), PAb242 (molar ratio of
2), and of S100B (4 µM).
|
|
The second peptide, YF-O2320-346 (residues 320-346 in
mouse p53) have sequence, structural, and functional homologies with
the basic helix I domain on myogenic basic helix-loop-helix proteins,
which is also capable of interacting with S100A1 or calmodulin (30, 32-34). We next analyzed the interaction of S100B with the
YF-O2320-346 peptide and its tryptophan derivative, W-O2.
In a competition assay, W-O2 is capable of antagonizing S100B binding
to the p53319-393-coated sensorship (Fig. 4A).
A physical interaction of S100B with W-O2 peptide was then demonstrated
by fluorescence spectroscopy, taking advantage of the fact that the
S100B protein has no Trp residue (Fig. 6,
A and B). Incubation of S100B with W-O2 in the presence of 0.1 mM CaCl2 resulted in a 25%
decrease in Trp fluorescence of the W-O2 peptide with a shift of the
maximum emission from 345 to 340 nm (Fig. 6A). We next
performed a dose-dependent titration of the fluorescence
intensity changes of the W-O2 peptide at concentrations (1 µM and 2 µM) far above the apparent
Kd determined with surface plasmon resonance.
Maximum change in Trp fluorescence intensity was observed at a molar
ratio of 0.5 mol S100B/mol W-O2, suggesting a stoichiometric binding of
one
subunit of S100B protein/W-O2 peptide molecule (Fig.
6B). In the presence of EGTA, significant decrease in Trp
fluorescence intensity can also be observed (Fig. 6B). These
changes are probably representative of low affinity and nonspecific
interactions. Native gel electrophoresis was also used to monitor
complex formation between S100B and W-O2 (Fig. 6C). Using
that method, low affinity Ca2+-independent interaction
could not be detected. Only high affinity Ca2+-dependent complex formation between S100B
and W-O2 was observed, as indicated by an upward shift of the S100B
band. Note that in the presence of Ca2+, the change in
electrophoretic mobility of S100B is due to conformational changes
induced upon Ca2+ binding (32).

View larger version (40K):
[in this window]
[in a new window]
|
Fig. 6.
S100B interacts with tryptophan-YF-O2 peptide
derivative (W-O2). A, Trp fluorescence spectra of W-O2
(1 µM) in 25 mM Tris-HCl, pH 7.5, O.12
M NaCl, 0.1 mM CaCl2 in the absence
(solid line) or in the presence (dashed line) of
S100B (1.4 µM). B, titration of the percentage
change in Trp fluorescence of W-O2 at the concentration of 1 µM ( ) or 2 µM ( , ) as a function
of S100B( )/W-O2 molar ratio in the presence of 0.1 mM
CaCl2 ( , ) or 2 mM EGTA ( ).
C, migration in native 13% polyacrylamide gel
electrophoresis plus either 1 mM EGTA or 0.5 mM
CaCl2, as indicated of S100B alone (lanes 1) or
mixed with W-O2 at molar ratio of 0.5 (lanes 2), 1 (lanes 3), and 2 (lane 4). The
arrowhead on the right points to S100 -W-O2
complex.
|
|
YF-O2320-346 corresponds to a putative PKC-binding domain
on p53. The YF-O2320-346 peptide binds to the catalytic
site of calcium-dependent PKC (PKC
,
, and
) with
affinity in the 50-100 nM range and inhibits kinase
activities (30). As previously reported, the interaction of
YF-O2320-346 with PKC results in a total inhibition of
O1357-381 peptide phosphorylation (Fig.
7A). The tryptophan derivative W-O2 was as potent as YF-O2320-346 in inhibiting
O1357-381 peptide phosphorylation (Fig. 7A). In
the presence of S100B, inhibition of O1357-381 peptide
phosphorylation is abrogated, suggesting that S100B competes with PKC
for binding on YF-O2 and W-O2 peptides (Fig. 7A). As expected, the half-maximum effect of S100B was dependent on the W-O2
peptide concentrations used in the assay (Fig. 7B). In all conditions, the maximum were reached for 0.5 mol S100B added per mol
peptide, confirming a stoichiometric binding of one S100-
subunit
per W-O2 or YF-O2 peptide molecule. Calmodulin or S100A6 counteracted
W-O2- and YF-O2-dependent inhibition of PKC activity only
at high concentrations (Fig. 7A). It has been proposed that YF-O2 domain might serve to target PKC on p53 and that it could be an
important potency determinant in p53 phosphorylation by PKC (30). The
ability of S100B to prevent YF-O2-PKC interaction might explain the
inhibitory effect of S100B on full-length p53 phosphorylation by
PKC (16).

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 7.
S100B counteracts YF-O2 and W-O2 inhibition
of PKC activity. A, inhibition of PKC activity by YF-O2
and W-O2 and release of this inhibition by S100B, S100A6, and
calmodulin. PKC activity was measured using O1 peptide as substrate.
B, titration curves of S100B-dependent release
of PKC in the presence of 0.6 µM ( ), 3.3 µM ( ), or 26 µM ( ) of W-O2
peptide.
|
|
 |
DISCUSSION |
In the first part of this study, we have confirmed that
baculovirus recombinant wild type p53 is highly sensitive to thermal denaturation (16). Temperature-dependent denaturation of
p53 is linked to protein aggregation (16) and compromised DNA binding activity of p53 (Fig. 2A). The interaction of S100B with
recombinant wild type p53 protects p53 from thermal denaturation (16;
Fig. 2, B and C). Secondly, we have confirmed a
specific and strict calcium-dependent interaction of the
S100B with a synthetic peptide derived from the C-terminal region of
p53 (residues 319-393 in human p53) by plasmon resonance measurement
experiments. We have also identified the YF-O2 peptide as part of a
high affinity S100B-binding site within the C-terminal region of p53.
Structural studies have shown that the YF-O2 sequence is a critical
domain for p53 thermostability (24, 25). It is likely that interaction
of S100B with YF-O2 peptide on p53 is directly responsible for the
increased resistance of p53 to thermal denaturation. Like S100B, the
E. coli heat shock protein DnaK has been shown to bind to
the C terminus of p53 and protect p53 from thermal denaturation (23,
26). S100B is the first mammalian protein to share this property with DnaK.
The YF-O2 peptide on p53 is involved in the dimerization and in
subsequent tetramerization of p53 dimers (28, 35-37). The Kd value found for the tetramer-monomer transition
of the C-terminal domain of p53 was determined to be 1-10
µM (28, 35). Because of the high Kd
value, it has been proposed that in normal, undamaged cells, when the
cytoplasmic p53 concentration is very low, p53 may be largely monomeric
(35). However in its monomeric state, the p53 molecule is
thermodynamically unstable relative to the tetramer (24, 25). The high
equilibrium affinity of the S100B for the C-terminal domain immobilized
on the sensor chip (Kd 24 ± 10 nM)
suggests that S100B could transiently interact with cytoplasmic p53
monomer to stabilize the p53 in a native conformation prior to nuclear
translocation. Once p53 has translocated to the cell nuclei, it may be
stabilized through its interactions with DNA targets as a tetramer. The
idea that S100B could be involved in conformational modulation and
stabilization of p53 monomer into a native (wild type) conformation is
supported by in vivo observations (5). In mouse embryo
fibroblast cells expressing low levels of the temperature-sensitive
p53val135 mutant, S100B cooperates with calcium in stabilization and
activation of the wild type p53val135 conformational species at the
nonpermissive temperature (37.5 °C) (5). The YF-O2 sequence on p53
also corresponds to a "cytoplasmic sequestration domain" (27).
Hence, one can envision that in response to intracellular calcium
elevation, S100B could also dissociate the interaction between p53 and
cytoplasmic anchoring proteins to favor p53 nuclear translocation. It
is noteworthy that in mouse embryo fibroblast cells expressing S100B
and the p53val135, calcium-mediated stabilization of the p53val135
under a wild type conformation is also associated with wild type
p53val135 nuclear accumulation (5). The involvement of calcium
signaling and S100B in activation of wild type p53 probably not only
concern the p53val135 mutant but could be of more general occurrence. Intracellular calcium elevation is induced in physiological stimulation known to activate p53 functions, including cell contact (38) and
hypoxia associated with tumor formation (39, 40). S100B, which is
normally expressed at low levels in proliferating glial cells or in
peripheral tissues, is also strongly induced by such stimulations. For
examples, in C6 glial cells, S100B synthesis correlates with
G1 phase growth arrest at confluence (5). In cardiac
myocytes, S100B is induced in response to hypoxia (41). This last
observation also suggests that overexpression of S100B generally
observed in brain tumors and peripheral tumors (42, 43) could be linked
to hypoxia during tumor formation (39). It is tempting to speculate
that in normal cells and also in tumor cells S100B induction could also
be associated with p53 activation.
Finally, the high affinity S100B-binding domain within p53 that we
identified also corresponds to the minimal transforming domain on
mutant p53 (Ref. 44 and Fig. 3). Overexpression of the transforming
C-terminal p53 mini-protein harboring YF-O2 domain cooperates with the
ras oncogene in cell transformation in the absence of
endogenous wild type p53 (45). This suggests that YF-O2-mediated
transformation operates via stable interaction and inactivation of p53
target proteins. Because ectopic expression of S100B in a REF cell line
overexpressing ras and the p53val135 is able to revert
transformed phenotypes of the cells, it would be worth investigating
whether S100B could also dissociate interactions between YF-O2 and
target proteins.
The Kd value found for the interaction between S100B
and the p53319-393 peptide (24 nM) is in the
same range as that reported for the interaction between the S100A1 and
the basic helix-loop-helix peptide of MyoD (20 nM)
(32-34). A conserved amino acid sequence exists within the YF-O2
sequence of p53 (344LNEALELK351) that is
implicated in S100B binding and the helix I motif within myogenic
transcription factor MyoD (124VNEAFETLK132)
involved in S100A1 binding. These two motifs are involved in the
regulation of p53 and MyoD cellular localization (27, 46). The
identification of a putative S100 target consensus motif within p53 and
MyoD with functional homologies suggests that regulation of nuclear
translocation of transcription factors associated with negative cell
growth regulation may be a general feature of S100 proteins function.
It is interesting to note that interaction of S100B and S100A1 with an
other nuclear protein, the Ndr protein kinase, has recently been
characterized (15). It would be interesting to study the possible
contribution of S100 proteins in Ndr protein kinase nuclear
translocation. Despite the strong amino acid sequence homology between
the YF-O2 sequence on p53 and the helix I motif on MyoD, the
interaction between p53319-393 peptide and S100B is
isoform-specific (Fig. 4C). Such specificity suggests that
in addition to the consensus sequence, other amino acids adjacent to
that motif could be responsible for the specificity of interaction
between S100B and p53. Weber's group (12, 18) recently reported that
S100B binds to a basic peptide derived from the extreme C-terminal
basic tail of human p53 (residues 367-388), which corresponds to the
O1 peptide. The high dissociation constant for this interaction
(Kd = 20 µM) (12, 18) would explain
why we have not been able to detect interaction of this peptide with
S100B (Fig. 5). In our experimental conditions, the low S100B
concentration used (4 µM) was probably not sufficient to
reveal low affinity interaction. It is nevertheless possible that O1
domain contribute to strengthen the interaction of S100B dimer with the
full-length C-terminal region of p53. The possible implication of O1 in
S100B binding to p53319-393 peptide may explain why
analysis of the kinetics of interactions between S100B and
p53319-393 immobilized on the sensor chip cannot be
analyzed with a single interaction site model at high S100B
concentration. Although O1 peptide is not involved in p53 dimerization
and tetramerization (24, 28, 35, 36), this domain is nevertheless
required for formation of higher oligomeric aggregates (37) and is
engaged in transient interchain interaction with another domain within the protein tetramer (35, 47). It is likely that, in addition to its
effect on wild type p53 stabilization, S100B could also affect an
important protein interaction at the C-terminal domain involving O1 domain.
 |
ACKNOWLEDGEMENT |
We thank Dr. Kuznicki for providing us with S100A6.
 |
FOOTNOTES |
*
This work was supported by grants from the Association pour
la Recherche sur le Cancer and La Ligue Nationale Contre le Cancer (to
J. B.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.

To whom correspondence should be addressed: INSERM Unité
244, DBMS-BRCE, CEA-Grenoble, 17 rue des Martyrs, 38054 Grenoble Cedex
9, France. Tel.: 33-476-88-43-28; Fax: 33-476-88-51-00; E-mail:
jbaudier{at}cea.fr.
 |
ABBREVIATIONS |
The abbreviation used is:
PKC, protein kinase
C.
 |
REFERENCES |
-
Schäfer, B. W.,
and Heizmann, C.
(1996)
Trends Biochem. Sci.
21,
134-140[CrossRef][Medline]
[Order article via Infotrieve]
-
Takahashi, K.,
Isobe, T.,
Ohtsuki, Y.,
Sonobe, H.,
Takeda, I.,
and Akagi, T.
(1984)
Am. J. Pathol.
116,
497-503[Abstract]
-
Fan, K.
(1982)
Brain Res.
237,
498-503[CrossRef][Medline]
[Order article via Infotrieve]
-
Marks, A.,
Petsche, D.,
O'Hanlon, D.,
Kwong, P. C.,
Stead, R.,
Dunn, R.,
Baumal, R.,
and Liao, S.-K.
(1990)
Exp. Cell Res.
187,
59-64[Medline]
[Order article via Infotrieve]
-
Scotto, C.,
Deloulme, J. C.,
Rousseau, D.,
Chambaz, E.,
and Baudier, J.
(1998)
Mol. Cell. Biol.
18,
4272-4281[Abstract/Free Full Text]
-
Drohat, A.,
Nenortas, E.,
Beckett, D.,
and Weber, D. J.
(1997)
Protein Sci.
6,
1577-1582[Abstract/Free Full Text]
-
Kilby, P. M.,
Van Eldik, L. J.,
and Roberts, G. C.
(1996)
Structure
4,
1041-1052[Medline]
[Order article via Infotrieve]
-
Baudier, J.,
Glasser, N.,
and Gerard, D.
(1986)
J. Biol. Chem.
261,
8192-8203[Abstract/Free Full Text]
-
Smith, P.,
and Shaw, G. S.
(1998)
Structure
6,
211-222[Medline]
[Order article via Infotrieve]
-
Baudier, J.,
and Gerard, D.
(1986)
J. Biol. Chem.
261,
8204-8212[Abstract/Free Full Text]
-
Ivanenkov, V.,
Jamieson, G. A.,
Gruenstein, E.,
and Dimlich, R. V. W.
(1995)
J. Biol. Chem.
270,
14651-14658[Abstract/Free Full Text]
-
Rustandi, R. R.,
Drohat, A. C.,
Baldisseri, D. M.,
Wilder, P. T.,
and Weber, D. J.
(1998)
Biochemistry
37,
1951-1960[CrossRef][Medline]
[Order article via Infotrieve]
-
Baudier, J.,
Briving, C.,
Deinum, J.,
Haglid, K.,
Sörskog, L.,
and Wallin, M.
(1982)
FEBS Lett.
147,
165-167[CrossRef][Medline]
[Order article via Infotrieve]
-
Bianchi, R.,
Giambanco, I.,
and Donato, R.
(1993)
J. Biol. Chem.
268,
12669-12674[Abstract/Free Full Text]
-
Millward, T. A.,
Heizmann, C. W.,
Schäfer, B. W.,
and Hemmings, B. A.
(1998)
EMBO J.
17,
5913-5922[Abstract/Free Full Text]
-
Baudier, J.,
Delphin, C.,
Grunwald, D.,
Khochbin, S.,
and Lawrence, J. J.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
11627-11631[Abstract]
-
Levine, A. J.,
Momand, J.,
and Finlay, C. A.
(1991)
Nature
351,
453-456[CrossRef][Medline]
[Order article via Infotrieve]
-
Wilder, P. T.,
Rustandi, R. R.,
Drohat, A. C.,
and Weber, D. J.
(1998)
Protein Sci.
7,
794-798[Abstract/Free Full Text]
-
Michalovitz, D.,
Halevy, O.,
and Oren, M.
(1990)
Cell
62,
671-680[Medline]
[Order article via Infotrieve]
-
Milner, J.
(1995)
Trends Biochem. Sci.
20,
49-51[CrossRef][Medline]
[Order article via Infotrieve]
-
Milner, J.,
and Medcalf, E. A.
(1991)
Cell
65,
765-774[Medline]
[Order article via Infotrieve]
-
Sabapathy, K.,
Klemm, M.,
Jaenisch, R.,
and Wagner, E. F.
(1997)
EMBO J.
16,
6217-6229[Abstract/Free Full Text]
-
Hansen, S.,
Hupp, T. R.,
and Lane, D. P.
(1996)
J. Biol. Chem.
271,
3917-3924[Abstract/Free Full Text]
-
Johnson, C. R.,
Morin, P. E.,
Arrowsmith, C. H.,
and Freire, E.
(1995)
Biochemistry
34,
5309-5316[Medline]
[Order article via Infotrieve]
-
Mateu, M. G.,
and Fersht, A.
(1998)
EMBO J.
17,
2748-2758[Abstract/Free Full Text]
-
Hansen, S.,
Midgley, C. A.,
Lane, D. P.,
Freemann, B. C.,
Morimoto, R.,
and Hupp, T. R.
(1996)
J. Biol. Chem.
271,
30922-30928[Abstract/Free Full Text]
-
Liang, S. H.,
Hong, D.,
and Clarke, M. F.
(1998)
J. Biol. Chem.
273,
19817-19821[Abstract/Free Full Text]
-
Sakamoto, H.,
Lewis, M. S.,
Kodama, H.,
Appella, E.,
and Sakaguchi, K.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
8974-8978[Abstract]
-
Delphin, C.,
Cahen, P.,
Lawrence, J. J.,
and Baudier, J.
(1994)
Eur. J. Biochem.
223,
683-692[Abstract]
-
Delphin, C.,
Huang, K. P.,
Scotto, C.,
Chapel, A.,
Vincon, M.,
Chambaz, E.,
Garin, J.,
and Baudier, J.
(1997)
Eur. J. Biochem.
245,
684-692[Abstract]
-
Shaulsky, G.,
Goldfinger, N.,
Ben-Ze'ev, A.,
and Rotter, V.
(1990)
Mol. Cell. Biol.
19,
6565-6577
-
Baudier, J.,
Bergeret, E.,
Bertacchi, N.,
Weintraub, H.,
Gagnon, J.,
and Garin, J.
(1995)
Biochemistry
34,
7834-7846[Medline]
[Order article via Infotrieve]
-
Hermann, S.,
Saarikettu, J.,
Onions, J.,
Hughes, K.,
and Grundström, T.
(1998)
Cell Calcium
23,
135-142[CrossRef][Medline]
[Order article via Infotrieve]
-
Onions, J.,
Hermann, S.,
and Grundström, T.
(1997)
J. Biol. Chem.
272,
23930-23937[Abstract/Free Full Text]
-
Sakaguchi, K.,
Sakamoto, H.,
Lewis, M. S.,
Anderson, C. W.,
Erickson, J. W.,
Appella, E.,
and Xie, D.
(1997)
Biochemistry
36,
10117-10124[CrossRef][Medline]
[Order article via Infotrieve]
-
Clore, M. G.,
Omichinski, J. G.,
Sakaguchi, K.,
Zambrano, N.,
Sakamoto, H.,
Appella, E.,
and Gronenborn, A. M.
(1994)
Science
265,
386-391[Medline]
[Order article via Infotrieve]
-
Sturzbecher, H. W.,
Brain, R.,
Addison, C.,
Rugbe, K.,
Remm, M.,
Grimaldi, M.,
Keenan, E.,
and Jenkins, J. R.
(1992)
Oncogene
7,
1513-1523[Medline]
[Order article via Infotrieve]
-
Yahanda, A. M.,
Bruner, J. M.,
Donehower, L. A.,
and Morrison, R. S.
(1995)
Mol. Cell. Biol.
15,
4249-4259[Abstract]
-
Kinzler, K.,
and Vogelstein, B.
(1996)
Nature
379,
19-20[CrossRef][Medline]
[Order article via Infotrieve]
-
Graeber, T. G.,
Osmanian, C.,
Jacks, T.,
Housman, D. E.,
Koch, C. J.,
Lowe, S. W.,
and Giaccia, A. J.
(1996)
Nature
379,
88-91[CrossRef][Medline]
[Order article via Infotrieve]
-
Tsoporis, J. N.,
Marks, A.,
Kahn, H. J.,
Butany, J.,
Liu, P. P.,
O'Hanlon, D.,
and Parker, T. G.
(1997)
J. Biol. Chem.
272,
31915-31921[Abstract/Free Full Text]
-
Nakajima, T.,
Watanabe, S.,
Sato, Y.,
Kameya, T.,
Hirota, T.,
and Shimosato, Y.
(1982)
Am. J. Surg. Pathol.
6,
715-727[Medline]
[Order article via Infotrieve]
-
Van Eldik, L. J.,
Jensen, R. A.,
Ehrenfried, B. A.,
and Whetsell, W. O.
(1986)
J. Histochem. Cytochem.
34,
977-982[Abstract]
-
Shaulian, E.,
Zauberman, A.,
Ginsberg, D.,
and Oren, M.
(1992)
Mol. Cell. Biol.
12,
5581-5592[Abstract]
-
Shaulian, E.,
Haviv, I.,
Shaul, Y.,
and Oren, M.
(1995)
Oncogene
10,
671-680[Medline]
[Order article via Infotrieve]
-
Vandromme, M.,
Cavadore, J. C.,
Bonnieu, A.,
Froeschlé, A.,
Lamb, N.,
and Fernandez, A.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
4646-4650[Abstract]
-
Hupp, T. R.,
Sparks, A.,
and Lane, D. P.
(1995)
Cell
83,
237-245[Medline]
[Order article via Infotrieve]
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.